25 June 2021 - Recommendation for approval based on results from pivotal KarMMa study.
Bristol Myers Squibb today announced the CHMP of the EMA has recommended granting conditional marketing authorisation for Abecma (idecabtagene vicleucel; ide-cel), the company’s B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.